Active substances
Isoniazid + Rifampicin
- SFDA 2
- US FDA 2
- NHS prices 2
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| RIFINAH | 150,100 mg,mg | Coated tablet · Oral use | 8 Blister | SAR 35.65 | Generic · Prescription | SANOFI S.P.A. | Valid |
| RIFINAH | 300,150 mg,mg | Coated tablet · Oral use | 8 Blister | SAR 64.45 | Generic · Prescription | SANOFI S.P.A. | Valid |
Indications — CHI Daman Drug Formulary
LATENT TUBERCULOSIS; PERITONITIS, PERITONEAL DIALYSIS-RELATED PERITONITIS; TUBERCULOSIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| RIFAMATE | 150MG;300MG | capsule · oral | SANOFI AVENTIS US | Discontinued | 11 Jul 1975 |
| RIFAMPIN AND ISONIAZID | 150MG;300MG | capsule · oral | HIKMA INTL PHARMS | Discontinued | 29 Jul 2005 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Rifampicin 150mg / Isoniazid 100mg tablets | £19.09 | 84 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Rifampicin 300mg / Isoniazid 150mg tablets | £25.22 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.5. Antituberculosis medicines · core
Tuberculosis
Oral > Solid > dispersible tablet: 50 mg + 75 mg (EMLc) | Oral > Solid > tablet: 75 mg + 150 mg (EML); 150 mg + 300 mg (EML)
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.